I got myself a new job. Here's how Canada News Wire reports the move:
Queen's University attracts first Ontario Research Chair
OTTAWA, April 4 /CNW Telbec/ - Queen's University has appointed the first of eight new Ontario Research Chairs in Public Policy - part of a $25-million provincial government initiative to address key policy issues.
A world leader in the study of health care ethics related to policy, Dr. Udo Schuklenk will be the Ontario Research Chair in Bioethics. Dr. Schuklenk was successfully recruited from Glasgow Caledonian University in Scotland, where he was professor and head of the Centre for Ethics in Public Policy and Corporate Governance.
"We are extremely pleased to welcome to Queen's such a highly accomplished scholar with significant research experience," says Principal Karen Hitchcock. "His outstanding publication record, international experience gained at universities in Australia, South Africa, Germany and Britain, and reputation for public service make Dr. Schuklenk an excellent choice for this new position. We look forward to his contributions to this important and highly complex area of public policy."
"We are delighted to welcome a scholar of Dr. Schuklenk's calibre and international reputation to Queen's University," said John Gerretsen, MPP Kingston and the Islands, on behalf of Chris Bentley, Minister of Training, Colleges and Universities. "Along with the remaining seven Ontario Research Chairs, we look forward to the benefits of an increased number of leading edge researchers at our universities who will help ensure that the next generation of graduate students is prepared to address issues and find novel solutions to problems of central relevance to all Ontarians."
Co-editor-in-chief of Bioethics, the official journal of the International Association of Bioethics, Dr. Schuklenk's publications in this area have been critically acclaimed. As Chair, he plans to examine the degree to which market forces should be allowed to dictate the direction of pharmaceutical research; how communities whose "local knowledge" is commercially exploited by pharmaceutical companies should be compensated; and how to define appropriate measures of infectious disease control in conditions of pandemic.